Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R

Pharmacogenetics

Volumn 11, Issue 2, 2001, Pages 123-134

  Watson, C E ^a   Draganov, D I ^a   Billecke, S S ^a   Bisgaier, C L ^a   La Du, B N ^a  

^a Esperion Therapeutics Inc   (United States)

Author keywords

Lactones; Lipoproteins; Oxidation; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ESTER DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LACTONE DERIVATIVE; NUCLEOTIDE DERIVATIVE; ORGANOPHOSPHATE;

ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CHROMOSOME Q BAND; DNA SEQUENCE; ENZYME SPECIFICITY; GENE ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LIPID OXIDATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RABBIT;

ANIMALS; ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; DNA PRIMERS; ESTERASES; EXONS; HAPLOTYPES; HOMOZYGOTE; HUMANS; ISOENZYMES; POLYMORPHISM, GENETIC; RABBITS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

ORYCTOLAGUS CUNICULUS;

EID: 0035107483     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200103000-00003     Document Type: Article

References (45)

1. Serum esterases I
2. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
3. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
4. Selective plasma hydrolysis of glucocorticoid g-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism
5. Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate
6. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters
7. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
8. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
9. Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase
10. Rabbit serum paraoxonase 3 (PON3) is an HDL-associated lactonase and protects LDL against oxidation
11. The human serum paraoxonase/arylesterase polymorphism
12. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent
13. Continuous monitoring of in vitro oxidation of human low density lipoprotein
14. Contributions to section V, rabbit: Inbred and partially inbred strains
15. Genetic and temporal determinants of pesticide sensitivity: Role of paraoxonase (PON1)
16. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities
17. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans
18. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence
19. Practical methods for plasma lipoprotein analysis
20. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities
21. Evaluation of serum-lipid-related cardiovascular risk factors in Alzheimer's disease
22. Comparison of purified human and rabbit serum paraoxonases
23. Calcium binding by human and rabbit serum paraoxonases
24. Human serum paraoxonase/arylesterase
25. The polymorphic paraoxonase/arylesterase isozymes of human serum
26. On the physiological role(s) of the paraoxonases
27. Paraoxonase as a risk marker for cardiovascular disease: Facts and hypotheses
28. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
29. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
30. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
31. Paraoxonase and coronary heart disease
32. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation
33. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease
34. The paraoxonase polymorphism in a Saudi Arabian population
35. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
36. Determination of paraoxonase (PON1) status requires more than genotyping
37. Atherosclerosis - An inflammatory disease
38. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
39. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase
40. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids
41. How different constituents of human plasma and low density lipoproteins determine plasma oxidizability by copper
42. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
43. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein
44. The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese
45. Paraoxonase polymorphism in rabbits